GU Cancers Symposium 2014 - Results from #100

GU Cancers Symposium 2014 - Results of subset analyses on overall survival from study CA184-043: Ipilimumab (Ipi) versus placebo in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Beyond enzalutamide and abiraterone: What’s next in androgen therapy? - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Novel long noncoding RNA-dependent mechanisms of androgen receptor-regulated gene activation - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Unleashing the power of the immune system through combination therapy - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Dissecting the biology of the androgen receptor pathway - Session Highlights January 30, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study - Session Highlights January 30, 2014

Myriad's Prolaris® test significantly modifies treatment decisions for patients with prostate cancer January 29, 2014

Symposium highlights latest research advances in GU cancers January 28, 2014

GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Impact of angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII) - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer - Slide Presentation January 28, 2014

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study - Abstract January 25, 2014

Myriad Genetics to present five clinical studies at 2014 ASCO GU Cancer Symposium January 23, 2014

Embargoed presscast on January 28 to feature key research advances in genitourinary cancers, embargoed press release now available January 23, 2014

Page 6 of 6